What is Zacks Research’s Forecast for Qiagen Q2 Earnings?

Qiagen N.V. (NYSE:QGEN) – Analysts at Zacks Research reduced their Q2 2026 earnings per share estimates for Qiagen in a report released on Wednesday, May 27th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.61 for the quarter, down from their previous estimate of $0.63. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Qiagen’s current full-year earnings is $2.43 per share. Zacks Research also issued estimates for Qiagen’s Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.65 EPS, FY2026 earnings at $2.44 EPS, Q1 2027 earnings at $0.60 EPS, Q2 2027 earnings at $0.63 EPS, Q3 2027 earnings at $0.68 EPS, Q4 2027 earnings at $0.72 EPS, FY2027 earnings at $2.63 EPS, Q1 2028 earnings at $0.67 EPS and FY2028 earnings at $2.88 EPS.

Qiagen (NYSE:QGEN) last announced its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.54. The business had revenue of $492.32 million for the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period last year, the firm posted $0.56 earnings per share.

Several other brokerages have also recently issued reports on QGEN. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research report on Thursday, April 30th. Robert W. Baird set a $43.00 target price on Qiagen and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. TD Cowen reissued a “hold” rating and issued a $40.00 target price (down from $46.00) on shares of Qiagen in a research report on Thursday, May 7th. UBS Group set a $52.00 price objective on Qiagen in a research report on Monday, February 9th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and a consensus price target of $44.98.

Qiagen Trading Up 1.7%

Shares of NYSE:QGEN opened at $36.15 on Thursday. The stock has a market capitalization of $7.45 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 3.54 and a beta of 0.64. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock’s 50-day simple moving average is $37.86 and its two-hundred day simple moving average is $44.87. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be paid a $0.35 dividend. This represents a yield of 104.0%. The ex-dividend date of this dividend is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio is presently 13.61%.

Institutional Trading of Qiagen

A number of large investors have recently added to or reduced their stakes in QGEN. Boston Partners bought a new stake in Qiagen in the 3rd quarter worth approximately $179,450,000. Norges Bank bought a new stake in Qiagen in the 4th quarter worth approximately $166,500,000. Dimensional Fund Advisors LP bought a new stake in Qiagen in the 3rd quarter worth approximately $58,079,000. Price T Rowe Associates Inc. MD increased its stake in Qiagen by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after acquiring an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in Qiagen by 9.7% in the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after acquiring an additional 697,342 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.